VolitionRX Ltd (VNRX) |
| 0.3319 -0.018 (-5.06%) 09-08 10:21 |
| Open: | 0.344 |
| High: | 0.344 |
| Low: | 0.3317 |
| Volume: | 349,494 |
| Market Cap: | 3(M) |
| PE Ratio: | -0.09 |
| Exchange: | New York Stock Exchange Arca |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 0.91 |
| Resistance 1: | 0.69 |
| Pivot price: | 0.41 |
| Support 1: | 0.33 |
| Support 2: | 0.27 |
| 52w High: | 14.8 |
| 52w Low: | 0.33 |
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Fri, 04 Sep 2026
$11M VolitionRx (VNRX) stake comes with call to cut executive pay - Stock Titan
Fri, 28 Aug 2026
Lind note deal lines up new VolitionRx (NYSE: VNRX) shares for resale - Stock Titan
Fri, 14 Aug 2026
Lagoda Investment discloses 14.0% VolitionRX (VNRX) stake in amended Schedule 13G - Stock Titan
Fri, 14 Aug 2026
Earnings call transcript: VolitionRX misses Q2 2026 estimates as shares slip - Investing.com
Thu, 13 Aug 2026
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update - Yahoo Finance
Thu, 13 Aug 2026
Earnings To Watch: VolitionRX Ltd (VNRX) Q2 2026 -- GF Value Sees 3914% Upside - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |